Helicobacter Pylori Non-Invasive Testing Market is predicted at a CAGR of 4.4% from 2023 to 2033
The global Helicobacter Pylori Non-Invasive Testing Market is expected to grow at a moderate 4.4% CAGR during the forecast period. The non-invasive helicobacter pylori testing market is currently valued at US$ 650.50 Mn in 2023. The demand for helicobacter pylori non-invasive testing is expected to reach $1 billion by 2033.
The increasing prevalence of Helicobacter pylori bacterial
infection, increased governmental awareness about infection for accurate
diagnosis, and the launch of new products and approval of those products by the
Food and Drug Administration are expected to drive the growth of the
helicobacter pylori non-invasive testing market. Although there is potential
for helicobacter pylori non-invasive testing demand, it is unlikely to
materialise due to issues such as a low detection rate, the absence of any
outward symptoms, and stringent regulatory constraints. Nonetheless, doctors
have advised patients to seek treatment for H. Despite the lack of evidence
linking COVID-19 and the virus, Pylori infections should be treated as soon as
possible.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15823
North America has the largest market share for non-invasive
Helicobacter pylori (H. pylori) testing, while Asia-Pacific has the fastest
growth. The North American helicobacter pylori non-invasive testing market is
expected to expand throughout the forecast period, owing to rising rates of
gastric cancer, duodenal ulcers, and gastric ulcers, as well as improvements in
healthcare infrastructure.
Throughout the forecast period, the market for non-invasive
H. pylori is expected to spread fastest in Asia Pacific. China, India, and
Japan are just a few of the countries in the region where non-invasive
helicobacter pylori testing is expected to grow rapidly in the coming years. As
Asia and the Pacific’s population ages, so does the prevalence of Helicobacter
pylori (H. pylori) and gastric cancer cases, so does the market for
non-invasive H. pylori testing. pylori is expected to spread. That is why there
is so much room for growth in the region for helicobacter pylori non-invasive
testing market players throughout the forecasted expansion period.
Key Takeaways
- The
rise in non-invasive testing for Helicobacter pylori (H. pylori) is
expected to drive demand for H. pylori non-invasive tests. pylori
diagnosis and a scarcity of endoscopic resources
- The
demand for non-invasive helicobacter pylori (H. pylori) testing is
increasing due to increased government awareness of infection and the need
for accurate diagnosis, rising demand for point-of-care testing equipment,
and the widespread availability of diagnostic tests.
- The
demand for helicobacter pylori (H. pylori) non-invasive testing is
expected to rise as a result of factors such as the increasing prevalence
of H. pylori. pylori infection, the introduction of new products, and the
Food and Drug Administration’s approval of these products
- The
global ageing population and the rising number of people with stomach
ulcers are expected to fuel the growth of the helicobacter pylori
non-invasive testing market.
- The
adoption of non-invasive testing for helicobacter pylori
(H. pylori) is expected to grow during the projected period due to rising
technical developments and an increase in innovations.
- The
demand for non-invasive tests to identify helicobacter
pylori (H. pylori) is projected to face challenges such as a low detection
rate, the fact that H. pylori infection often has no symptoms, and strict
regulatory regulations.
Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15823
Competitive Landscape
The global helicobacter pylori non-invasive testing market
comprises of the following players: Meridian Bioscience, Inc., DiaSorin S.p.A,
Alere, Sekiusi Diagnostics and Biomerica, Inc. Besides these, a host of other
players have a significant market presence as well. These are Biohit Oyj,
Exalenz Bioscience Ltd., Aalto Bio Reagents Ltd., Certest Biotec S.L. and
CorisBioconcept SPRL.
Recent Developments
Meridian Bioscience, Inc. has received FDA approval to
market its novel Curian and Curian HpSA assays in March 2020. The new analyzer
and preliminary assay are critical components of their strategy to maintain
market dominance in gastrointestinal disease testing.
Thermo Fischer Scientific, a world-renowned provider of
clinical research services to the biopharma and biotech industries, announced
in December 2021 that it is expected to acquire PPD, Inc. for US$17.4 billion.
Buy Now@ https://www.futuremarketinsights.com/checkout/15823
Key Segments in the Helicobacter Pylori Non-Invasive
Testing Market
By Non-invasive Test Type:
- Serology
Test
- Stool
Antigen Test
- Urea
Breath Test
By Test Type:
- Laboratory-based
Tests
- Point-of-Care
Tests
By End-user:
- Hospitals
- Diagnostic
Labs
- Clinics
Comments
Post a Comment